Technology ID
E-178-2014-0

Recombinant HIV-1 Envelope Protein for Vaccine Use

Linked ID
TAB-3338
Inventors
Ivelin Georgiev (NIAID)
Jason Gorman (NIAID)
Marie Pancera (NIAID)
Michael Joyce (NIAID)
Peter Kwong (NIAID)
Priyamvada Acharya (NIAID)
Tongqing Zhou (NIAID)
Lead Inventors
Peter Kwong (NIAID)
Co-Inventors
Ivelin Georgiev (NIAID)
Jason Gorman (NIAID)
Marie Pancera (NIAID)
Michael Joyce (NIAID)
Priyamvada Acharya (NIAID)
Tongqing Zhou (NIAID)
ICs
NIAID
Commercial Applications
  • Vaccine for prevention of HIV-1 infection.
  • Therapeutic vaccine for treatment of HIV-1 infection.
In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center (“VRC”) continue to study the structure of HIV-1. Recently, these researchers have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation.

The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response. The VRC researchers engineered a portion of the HIV-1 Env trimer to stabilize it in this closed conformation for use as an immunogen.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.
Competitive Advantages
  • Currently, no licensed HIV-1 vaccine exists.

Request More Info

Licensing Contact